Home
Solution
Impact
R&D
Science
Publications
STEP study
Xinnate’s Expanded Access Policy
About
Team and Board
News and Events
All News
All Events
All Press Releases
Contact
Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa
Home
News
Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa
Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa
Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa
